Acasti Pharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

 

Registrant’s telephone number, including area code: (609) 322-1602

Acasti Pharma Inc.

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

---

 

On October 24, 2024, Grace Therapeutics, Inc. (the “Company”) filed a certificate of amendment (the “Certificate of Amendment”) to its Certificate of Incorporation with the Secretary of State of the State of Delaware solely to change the Company’s name from “Acasti Pharma Inc.” to “Grace Therapeutics, Inc.” The name change became effective on October 28, 2024. A copy of the Certificate of Amendment is attached as Exhibit 3.1 hereto and incorporated herein by reference.

 

In connection with the name change, the Company’s Board of Directors amended the Company’s Bylaws (the “Bylaws”) to reflect the Company’s name change, also effective October 28, 2024. No other changes were made to the Bylaws. A copy of the Bylaws reflecting this amendment is attached as Exhibit 3.2 hereto and incorporated herein by reference.

 

The Company’s common stock previously traded on the Nasdaq Stock Market under the ticker symbol “ACST” and, effective as of October 28, 2024, is trading on the Nasdaq Stock Market under the new ticker symbol “GRCE”.

 

The name change does not affect the rights of the Company’s security holders, and the CUSIP number for the Company’s common stock will continue to be 00439U104.

 

(d) Exhibits

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

---